肿瘤放射增敏剂在鼻咽癌放射治疗的临床价值

Clinical value of tumor radiosensitizer in the radiation therapy of nasopharyngeal carcinoma

目的探讨肿瘤放射增敏剂希美钠(CMNa)在鼻咽癌放射治疗的增敏作用和临床价值。方法回顾分析综合组(希美钠+放射治疗组)和单纯组(放射治疗组)各35例。综合组采用希美钠800mg/m2,用100ml生理盐水稀释溶解,于30min内完成静脉滴注,在60min内进行放射治疗。2～3次/周,连续用药至放射治疗结束,用药总量为6000～9000mg。单纯组仅单纯采用放射治疗。结果近期疗效综合组明显高于单纯组,其放射治疗疗效提高37.14%,远期疗效正进一步观察中。结论希美钠不良反应小,安全性高,对鼻咽癌放射治疗增敏效果显著。

Objective To discuss the clinical value and sensitizing effect of tumor radiosensitizer （ CM- Na） in the radiation therapy of Nasopharyngeal Carcinoma（NPC）. Methods 35 cases integrated group （CM-Na ＋ radiotherapy） and 35 cases simple group （radiotherapy） by recalling analysis. Integrated group use CM-Na 800 mg/m^2, diluted with 0.9% normal saline 100 ml, within 30 minutes intravenous drip at 60 minutes to radiation therapy. The medication was sequentially used till the end of radiation therapy. The frequency is two or three times per week and the mediation total is 6000-9000 mg. Simple group only used radiation therapy. Resuits Short-term effect of the integrated group was higher than simple group, with the effect of radiation therapy effect increased 37.14% and long-term effect is further observation. Conclusion CMNa is reaction of small, safe, the NPC sensitizing effects of radiation therapy significantly.